How berberine affects blood sugar

Berberine can lower blood sugar: clinical trials in people with type 2 diabetes, prediabetes or insulin resistance report lower fasting glucose and a drop in HbA1c, the long-term blood sugar marker. Whether people with normal starting values also gain a meaningful benefit is much less clear. Many studies are small and run for only short periods. Any decision also has to weigh possible side effects and interactions with medicines.

What berberine is and how it affects glucose metabolism

Berberine is a yellow alkaloid, a nitrogen-containing plant compound. It is extracted from plants including barberry, goldenseal and Oregon grape (common mahonia). Traditional Chinese and Ayurvedic medicine have used it for centuries, mostly for gastrointestinal infections. One of its pharmacological effects is the activation of AMP-activated protein kinase, or AMPK, an enzyme that regulates the energy metabolism of cells.

When AMPK is activated, cells use more energy and store less of it. Several downstream processes follow:

• Muscle and fat cells take up more glucose when the glucose transporter GLUT4 moves to the cell membrane.
• The liver makes less new glucose. This production of new glucose is called hepatic gluconeogenesis.
• When the mitochondria, the energy-supplying parts of the cell, work better, the cell can use energy more efficiently.

Berberine acts primarily as a drug-like compound. There is no such thing as a berberine deficiency that taking it could correct. A supplement delivers amounts far higher than anything you would get from food. That matters when judging dose, duration of use and the effect you can expect.

What clinical trials show about blood sugar control

Several randomized controlled trials report that fasting glucose (blood sugar measured after not eating) fell by 15 to 25 mg/dL in people with type 2 diabetes or prediabetes. In these trials, participants are randomly assigned to a treatment group or a comparison group. Over 8 to 12 weeks, HbA1c often fell by 0.5 to 1.0 percentage points. This value reflects how much glucose is bound to hemoglobin, the red pigment in blood, and serves as a measure of blood sugar over the longer term. Head-to-head comparisons with metformin found changes of similar size. However, the trials had fewer participants and shorter follow-up, so the clinical evidence for the two is not equivalent.

Insulin sensitivity is assessed, among other ways, with HOMA-IR. This index is calculated from fasting glucose and fasting insulin and estimates how far the action of insulin is reduced. Some studies report drops of 40 to 50 % from baseline. That points to improved insulin sensitivity and is also consistent with less insulin resistance in the liver. The index does not, however, directly measure how well insulin receptors work. A 2023 review covers the underlying mechanisms. Fasting insulin often falls along with glucose. Berberine might therefore affect both high blood sugar (hyperglycemia) and the extra insulin release the body uses to try to make up for weaker insulin action (hyperinsulinemia).

Whether berberine lowers blood sugar by a meaningful extra amount in people with normal glucose values and normal insulin sensitivity remains unclear. Most studies looked at people with raised fasting glucose or diagnosed diabetes. Their results cannot be reliably applied to healthy adults who want to improve their metabolism. How much insulin sensitivity changes depends largely on starting values.

The AMPK pathway: what berberine has in common with calorie restriction

AMPK is sometimes described as a master metabolic switch. When a cell is short of energy, the ratio of AMP to ATP rises. ATP is an immediately usable energy carrier; a higher share of AMP signals an energy shortfall. AMPK then switches on catabolic pathways that break down glucose and fat for energy. At the same time, the enzyme holds back building processes such as the synthesis of fat and protein. Exercise, fasting and eating fewer calories (also called calorie restriction) activate AMPK. Berberine can act on this pathway too. Taking it does not, however, replace the full range of effects of exercise or calorie restriction.

Activating AMPK promotes the movement of GLUT4 to the cell membrane in muscle and fat tissue. This lets glucose enter cells even independently of insulin. This mechanism could explain why berberine can lower blood sugar even in marked insulin resistance. Something similar happens when muscles contract during physical activity: contractions also promote the shift of GLUT4 through AMPK-dependent pathways.

AMPK also inhibits hepatic gluconeogenesis, the liver’s production of new glucose from substances that are not carbohydrates. In type 2 diabetes, excess glucose output by the liver contributes substantially to high fasting values. If this process is inhibited, the liver may release less glucose. That could explain why fasting glucose falls more in many studies than postprandial glucose, the blood sugar level after a meal.

AMPK also promotes the breakdown of fatty acids for energy and inhibits lipogenesis, the production of new fat. These processes may contribute to berberine’s observed effects on the blood lipids triglycerides and LDL cholesterol. They are also one reason berberine is marketed for weight loss. The evidence for meaningful loss of body fat in humans is, however, much weaker than the evidence for changes in glucose and blood lipids.

Which amounts, forms and timings have been studied

Dose

Clinical trials usually use 900 to 1,500 mg a day, split into two or three doses. The daily amount is often taken with several meals. To improve tolerability, some describe starting with 300 to 500 mg once or twice a day and then increasing gradually. This is meant to reduce gastrointestinal complaints and make it easier to judge tolerability. These figures describe dosing schedules that have been studied or reported; they are not an individual dosing recommendation.

The 2023 meta-analysis cited in this context examines, according to its title, the effect of berberine and barberry on inflammatory markers. It is therefore not directly relevant evidence for a dose to lower blood sugar.

Berberine is reported to have a short half-life of about 5 to 6 hours. The half-life is the time it takes for the concentration of a substance to fall by half. This short duration is the rationale for splitting the daily dose: taking the whole amount at once would make the concentration rise more sharply and then drop quickly. Divided doses are meant to keep the effect going longer. That alone does not show a correspondingly sustained AMPK activation in humans, however.

Form

Most clinical trials use berberine hydrochloride, also called berberine HCl. This form is also standard in supplements. Berberine sulfate and other salts are available too. Solid evidence that these alternatives are absorbed better or work better is lacking. Some newer products use liposomal or phytosome formulations, in which berberine is combined with lipid structures to improve absorption. So far there are only limited clinical data on these forms.

Oral bioavailability is reported at about 5 %, meaning the share of a swallowed dose that reaches the general circulation. The reasons given for this low share are poor absorption in the gut and extensive first-pass metabolism: a large part is broken down on its first pass through the liver. This partly explains why the doses studied are relatively high compared with other alkaloids. The low bioavailability also suggests that part of the effect may arise directly in the gut. There, berberine can influence the composition of the gut microbiota (the microorganisms living there) and the release of incretins. Incretins are gut hormones involved in regulating blood sugar.

Timing

Taking berberine around a meal is meant to improve tolerability, since berberine can cause gastrointestinal complaints on an empty stomach. It is also meant to line up the blood-sugar-lowering effect with the rise in glucose after eating. Taking it 30 minutes before or during a meal is described. The mechanistic reasoning behind this is that AMPK activation and the shift of GLUT4 could then coincide with the absorption of glucose from food. This does not yet reliably establish an optimal timing for each person.

Combinations

Berberine does not need specific cofactors, meaning additional substances it depends on to work, as some nutrients do. It can, however, interact with other supplements and with medicines. Berberine inhibits several enzymes of the cytochrome P450 system, especially CYP3A4. This enzyme breaks down many medicines. When it is inhibited, drug levels in the blood, and with them the risk of side effects, can rise. This affects certain statins, blood pressure medicines and immunosuppressants, among others. These interactions are documented and must be assessed by a doctor.

Together with other blood-sugar-lowering supplements or medicines, berberine can raise the risk of hypoglycemia, meaning blood sugar that falls too low. In people treated with metformin, sulfonylureas or insulin, adding berberine can contribute to blood sugar dropping too far. Whether such a combination is appropriate, and whether doses need adjusting, is therefore a decision for a doctor.

Who is most likely to respond to berberine, and who should be careful

The blood-sugar-lowering effect is clearest in people with raised starting values and insulin resistance. A measurable change is more likely when fasting glucose is above 100 mg/dL, HbA1c is in the prediabetic or diabetic range, or HOMA-IR points to insulin resistance. With normal glucose metabolism, the effects are smaller and less consistent. A single lab value, however, is not enough to decide on a suitable treatment.

Berberine also seems more likely to produce meaningful changes in dyslipidemia, a disorder of blood lipid levels. If triglycerides or LDL cholesterol are raised, its effects on fat metabolism could be clinically significant. That is why berberine is also being studied in the context of metabolic syndrome, where problems with glucose regulation and blood lipids often occur together.

Particular caution is needed in pregnancy and breastfeeding. Berberine crosses the placenta and has been linked to the risk of kernicterus in newborns, a form of brain damage caused by bilirubin. Other risk groups include people prone to low blood sugar, people on blood-sugar-lowering treatment and people taking medicines broken down by CYP3A4. Berberine can also cause diarrhea, constipation and abdominal cramps, especially at higher doses or when first starting.

Caution is also advisable in older people and in people with reduced kidney or liver function. Their bodies may break down or excrete berberine more slowly, so side effects may be stronger. There are only limited data on the safety of continuous use for more than 12 months. With longer-term use, follow-up by a doctor is therefore important. Occasional breaks from taking it are suggested as a precaution; that does not show they improve long-term safety.

How biomarkers can be used to judge changes

Measurable biological values, known as biomarkers, can show whether the targeted metabolic values are changing. Symptoms alone are not a reliable yardstick: changes in blood sugar often cause symptoms only when they are pronounced. Measurements before and during use allow a comparison with baseline values.

Fasting glucose, HbA1c and fasting insulin describe different aspects of glucose regulation and insulin sensitivity. HOMA-IR can also be calculated from fasting glucose and fasting insulin. A repeat comparison after 8 to 12 weeks of regular use matches the duration of many studies. The orders of magnitude given for a possible response are a drop in fasting glucose of at least 10 mg/dL, a fall in HbA1c of 0.3 to 0.5 percentage points or an improvement in HOMA-IR of at least 20 %. These figures are not universal thresholds for clinical benefit. How to interpret them depends on starting values and the treatment situation.

Blood lipids can also help with the assessment. Total cholesterol, LDL, HDL and triglycerides can be compared before starting and again after 8 to 12 weeks. Changes in blood lipids can be about as marked as changes in glucose values. Looking at both areas gives a fuller picture of the metabolic response.

If blood sugar control is the main focus, fructosamine is a possible additional marker. It reflects average blood sugar over the past 2 to 3 weeks. That means it can show shorter-term changes that are not yet visible in HbA1c, which can help a doctor assess changes in dose or timing.

Measurements can also help avoid taking something unnecessarily. If glucose, insulin and lipid values are already favorable, a meaningful extra benefit is less likely. If raised values fall during use, that change can be documented objectively. A before-and-after comparison alone, however, does not prove that berberine is the cause.

What baseline values mean for interpretation

To judge possible changes from berberine, the baseline values for glucose, insulin sensitivity and blood lipids need to be known. For berberine as a supplement, there is evidence of metabolic effects. Whether these matter in an individual case depends largely on which values are raised: berberine could help lower them. If values are already favorable, any additional benefit remains unclear.

Frequently asked questions

What is AMPK, and how does berberine affect this enzyme?

AMPK stands for AMP-activated protein kinase. The enzyme regulates energy metabolism and is activated when a cell is short of energy. The cell then uses more energy and stores less of it. As GLUT4 moves to the cell membrane, muscle takes up more glucose. At the same time, glucose production in the liver is inhibited and the breakdown of fatty acids is promoted. Berberine acts on this pathway pharmacologically and so mimics some of the metabolic processes of exercise, fasting and calorie restriction. These mechanisms can also help lower fasting glucose independently of insulin.

How does berberine compare with metformin in clinical trials?

Direct randomized comparison trials report reductions in fasting glucose similar to those with metformin. On berberine, HbA1c fell by 0.5 to 1.0 percentage points over 8 to 12 weeks. The berberine trials, however, had fewer participants and shorter follow-up than the metformin trials, so the evidence base is correspondingly narrower. Reductions in triglycerides and LDL cholesterol are also described, which do not consistently occur with metformin. The results neither show that the clinical evidence is equivalent nor justify switching treatment on your own.

Why is berberine taken with meals and split into several doses?

Berberine is reported to have a half-life of roughly 5 to 6 hours. A single daily dose therefore causes a sharper rise in concentration followed by a rapid fall. Splitting it across meals, typically 300 to 500 mg two or three times a day, is meant to give more even levels and a longer-lasting effect. Food can also reduce the gastrointestinal complaints that occur when it is taken on an empty stomach. Another idea is to match the blood-sugar-lowering effect to the rise in glucose from the meal’s carbohydrates. That this keeps AMPK continuously active is a mechanistic assumption. An optimal dosing schedule has not been established.

Does berberine work with normal blood sugar too, or only with insulin resistance?

The clinical data come almost entirely from studies of people with raised fasting glucose, prediabetes or type 2 diabetes. In existing insulin resistance, drops of 40 to 50 % in HOMA-IR and of 15 to 25 mg/dL in fasting glucose have been reported. With normal glucose metabolism and normal insulin sensitivity, the changes are smaller and less consistent. A meaningful benefit for metabolically healthy adults cannot be reliably inferred from this.

What effect does berberine have on LDL cholesterol and triglycerides?

Activating AMPK promotes the breakdown of fatty acids and inhibits lipogenesis, the production of new fat. These mechanisms may help lower triglycerides and LDL cholesterol, including beyond any improvement in glucose regulation. In clinical trials, blood lipid values can change about as markedly as blood sugar values. That is relevant in metabolic syndrome, where high triglycerides, high LDL and insulin resistance can occur together. Berberine is therefore studied for possible effects on both glucose and blood lipids, while for other supplements the focus is mainly on blood sugar.

Who should not take berberine for safety reasons?

People who are pregnant or breastfeeding should not take berberine. It crosses the placenta, and there are concerns about possible kernicterus, a form of brain damage in newborns. With medicines metabolized by CYP3A4 there is a documented risk of interaction. These include certain statins, blood pressure medicines and immunosuppressants: berberine inhibits the enzyme and can therefore raise the levels of these drugs. Nor should berberine be added on your own to existing treatment with metformin, sulfonylureas or insulin. The extra lowering of blood sugar can make hypoglycemia more likely. A doctor must therefore assess whether the combination is appropriate and whether the dose needs adjusting.

How long does it take for fasting glucose or HbA1c to change measurably?

Many clinical trials assess results after 8 to 12 weeks of use. The orders of magnitude given for a possible response are a drop in fasting glucose of at least 10 mg/dL, a fall in HbA1c of 0.3 to 0.5 percentage points or an improvement in HOMA-IR of at least 20 %. Whether such changes are clinically relevant depends on the starting value and the individual situation. HbA1c reflects average blood sugar over roughly 3 months. Short-term changes in glucose can therefore show up before HbA1c changes accordingly. Fructosamine covers a period of 2 to 3 weeks and can provide additional information sooner after changes in dose or timing.

Which biomarkers are suitable before and after starting, to judge an effect?

Fasting glucose, HbA1c and fasting insulin, together with the HOMA-IR calculated from them, describe the baseline state of glucose regulation and insulin sensitivity. Total cholesterol, LDL, HDL and triglycerides add the blood lipids to the picture. A repeat comparison after 8 to 12 weeks of regular use can make changes visible. If neither glucose nor lipid values improve meaningfully, that argues against a measurable benefit in these areas. Fructosamine can give earlier signs of changes in blood sugar between HbA1c tests, which are done at longer intervals. Which measurements make sense depends on the clinical question. Changes on their own do not prove that berberine caused them.

References

1. Vahedi-Mazdabadi Y, Shahinfar H, Toushih M, Shidfar F (2023). Effects of berberine and barberry on selected inflammatory biomarkers in adults: A systematic review and dose-response meta-analysis of randomized clinical trials. Phytotherapy research : PTR, 37(12), 5541-5557. https://doi.org/10.1002/ptr.7998. PubMed.

2. Askari VR, Khosravi K, Baradaran Rahimi V, Garzoli S (2023). A Mechanistic Review on How Berberine Use Combats Diabetes and Related Complications: Molecular, Cellular, and Metabolic Effects. Pharmaceuticals (Basel, Switzerland), 17(1). https://doi.org/10.3390/ph17010007. PubMed.

3. Guo J, Chen H, Zhang X, Lou W, Zhang P, Qiu Y, Zhang C, Wang Y, Liu WJ (2021). The effect of berberine on metabolic profiles in type 2 diabetic patients: A systematic review and meta-analysis of randomized controlled trials. Oxidative Medicine and Cellular Longevity, 2021, 2074610. https://doi.org/10.1155/2021/2074610. PubMed.

4. Liang Y, Xu X, Yin M, Zhang Y, Huang L, Chen R, Ni J (2019). Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: A systematic literature review and a meta-analysis. Endocrine Journal, 66(1), 51-63. https://doi.org/10.1507/endocrj.EJ18-0109. PubMed.

5. Wang J, Bi C, Xi H, Wei F (2024). Effects of administering berberine alone or in combination on type 2 diabetes mellitus: A systematic review and meta-analysis. Frontiers in Pharmacology, 15, 1455534. https://doi.org/10.3389/fphar.2024.1455534. PubMed.